1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Bio-Techne Corporation

Bio-Techne Corporation

TECH
Bio-Techne CorporationUS flagNASDAQ
72.61
USD
+0.04
- -
11.37BMarket Cap

Total Valuation

Bio-Techne Corporation carries a market capitalization of 11.37B, placing it among publicly traded companies globally. Its enterprise value stands at 11.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap11.37B
Enterprise Value11.05B

Share Statistics

Bio-Techne Corporation currently has 156.10M shares outstanding.

Shares Outstanding156.10M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Bio-Techne Corporation trades at a trailing price-to-earnings ratio of 60.58. The price-to-sales ratio is 9.07, and the price-to-book ratio stands at 5.23.

PE Ratio60.58
PS Ratio9.07
PB Ratio5.23
P/TBV Ratio13.30
P/FCF Ratio34.55
P/OCF Ratio37.72

Enterprise Valuation

On an enterprise value basis, Bio-Techne Corporation trades at an EV/EBITDA multiple of 29.87 and an EV/FCF ratio of 33.68. The EV/Sales ratio of 9.10 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 40.54 provides insight into valuation relative to core operating earnings.

EV / Sales9.10
EV / EBITDA29.87
EV / EBIT40.54
EV / FCF33.68

Financial Position

Bio-Techne Corporation maintains a current ratio of 4.55, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.71, indicating elevated leverage, while an interest coverage ratio of 38.42 demonstrates strong ability to service its debt obligations.

Current Ratio4.55
Quick Ratio2.94
Debt / Equity13.71
Debt / EBITDA0.78
Interest Coverage38.42

Financial Efficiency

Bio-Techne Corporation posts a return on equity of 9.03 and a return on invested capital of 8.64.

Return on Equity (ROE)9.03
Return on Assets (ROA)7.07
Return on Invested Capital (ROIC)8.64
Return on Capital Employed (ROCE)7.95
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.16

Taxes

Over the trailing twelve months, Bio-Techne Corporation has paid 58.82M in income taxes, reflecting an effective tax rate of 24.44.

Income Tax58.82M
Effective Tax Rate24.44

Stock Price Statistics

Bio-Techne Corporation's stock has gained approximately 43.83914% over the past 52 weeks. The 50-day moving average sits at 72.19, while the 200-day moving average is 61.65.

Beta (5Y)N/A
52-Week Price Change43.83914%
50-Day Moving Average72.19
200-Day Moving Average61.65
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Bio-Techne Corporation generated 1.22B in revenue and converted that into 181.86M in net income, yielding earnings per share of 1.16. EBITDA reached 369.97M, while operating income came in at 272.61M.

Revenue1.22B
Gross Profit799.07M
Operating Income272.61M
Pretax Income240.68M
Net Income181.86M
EBITDA369.97M
EBIT272.61M
Earnings Per Share (EPS)1.16

Balance Sheet

Bio-Techne Corporation holds 264.71M in cash and equivalents against 289.09M in total debt, resulting in a net debt position of -64.71M. Total book value stands at 2.11B, with working capital of 580.70M providing operational flexibility.

Cash & Cash Equivalents264.71M
Total Debt289.09M
Net Debt-64.71M
Equity (Book Value)2.11B
Book Value Per Share13.51
Working Capital580.70M

Cash Flow

Bio-Techne Corporation produced 292.07M in operating cash flow over the past twelve months. After subtracting -28.85M in capital expenditures, free cash flow totaled 263.22M - equivalent to 1.69 per share.

Operating Cash Flow292.07M
Capital Expenditures-28.85M
Free Cash Flow263.22M
FCF Per Share1.69

Margins

Bio-Techne Corporation operates with a gross margin of 65.77, reflecting its pricing power and cost economics. The operating margin of 22.44 and net profit margin of 14.97 provide insight into operational efficiency.

Gross Margin65.77
Operating Margin22.44
Pretax Margin19.81
Profit Margin14.97
EBITDA Margin30.45

Dividends & Yields

The company's payout ratio of 27.45 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.32
Dividend YieldN/A
Payout Ratio27.45
Shareholder Yield1.53
FCF Yield2.89

Stock Splits

Bio-Techne Corporation's most recent stock split took place on November 30, 2022 with a 1:4 split ratio.

Last Split Date11/30/2022
Split Ratio1:4

Scores

Bio-Techne Corporation posts an Altman Z-Score of 17.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score17.20